Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2

被引:61
|
作者
Otyepka, M
Krystof, V
Havlícek, L
Siglerová, V
Strnad, M
Koca, J
机构
[1] Masaryk Univ, Fac Sci, Lab Biomol Struct & Dynam, CS-61137 Brno, Czech Republic
[2] Palacky Univ, Fac Sci, Dept Inorgan & Phys Chem, Olomouc 77146, Czech Republic
[3] Palacky Univ, Fac Sci, Lab Growth Regulators, Olomouc 78371, Czech Republic
[4] Inst Expt Bot, Olomouc 78371, Czech Republic
[5] Charles Univ Prague, Fac Med 1, Cent Radioisotope Lab, Prague 12108 2, Czech Republic
[6] Inst Expt Bot, Isotope Lab, Prague 14220 4, Czech Republic
关键词
D O I
10.1021/jm990506w
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The cell division cycle is controlled by cyclin-dependent kinases (cdk), which consist of a catalytic subunit (cdk1-cdk8) and a regulatory subunit (cyclin A-H). Purine-like inhibitors of cyclin-dependent kinases have recently been found to be of potential use as anticancer drugs. Rigid and flexible docking techniques were used for analysis of binding mode and design of new inhibitors. X-ray structures of three (ATP, olomoucine, roscovitine) cdk2 complexes were available at the beginning of the study and were used to optimize the docking parameters. The new potential inhibitors were then docked into the cdk2 enzyme, and the enzyme/inhibitor interaction energies were calculated and tested against the assayed activities of cdk1 (37 compounds) and cdk2 (9 compounds). A significant rank correlation between the activity and the rigid docking interaction energy has been found. This implies that (i) the rigid docking can be used as a tool for qualitative prediction of activity and (ii) values obtained by the rigid docking technique into the cdk2 active site can also be used for the prediction of cdk1 activity. While the resulting geometries obtained by the rigid docking are in good agreement with the X-ray data, the flexible docking did not always produce the same inhibitor conformation as that found in the crystal.
引用
收藏
页码:2506 / 2513
页数:8
相关论文
共 50 条
  • [21] Cyclin-dependent kinase inhibitors and hepatocarcinogenesis
    Hui, AM
    Sakamoto, M
    Kanai, Y
    Ino, Y
    Gotoh, M
    Hirohashi, S
    RECENT ADVANCES IN GASTROENTEROLOGICAL CARCINOGENESIS I, 1996, : 481 - 485
  • [22] Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A
    Schulman, BA
    Lindstrom, DL
    Harlow, E
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (18) : 10453 - 10458
  • [23] Molecular Docking Simulation Studies of Curcumin and Its Derivatives as Cyclin-Dependent Kinase 2 Inhibitors
    Sumirtanurdin, Riyadi
    Sungkar, Shafira
    Hisprastin, Yasarah
    Sidharta, Kenny Dwi
    Nurhikmah, Dea Dian
    TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 17 (04) : 417 - 423
  • [24] Recent advances in the development of cyclin-dependent kinase 7 inhibitors
    Teng, Yuou
    Lu, Kui
    Zhang, Qian
    Zhao, Lianbo
    Huang, Yuna
    Ingarra, Angela Maria
    Galons, Herve
    Li, Tingshen
    Cui, Shanshan
    Yu, Peng
    Oumata, Nassima
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 183
  • [25] Cyclin-dependent kinase inhibitors in the development of the central nervous system
    Cunningham, JJ
    Roussel, MF
    CELL GROWTH & DIFFERENTIATION, 2001, 12 (08): : 387 - 396
  • [26] Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
    Chohan, Tahir Ali
    Qian, Haiyan
    Pan, Youlu
    Chen, Jian-Zhong
    CURRENT MEDICINAL CHEMISTRY, 2015, 22 (02) : 237 - 263
  • [27] Functional flexibility of human cyclin-dependent kinase-2 and its evolutionary conservation
    Bartova, Iveta
    Koca, Jaroslav
    Otyepka, Michal
    PROTEIN SCIENCE, 2008, 17 (01) : 22 - 33
  • [28] Synthesis of an 18F-labeled cyclin-dependent kinase-2 inhibitor
    Svensson, Frieda
    Kniess, Torsten
    Bergmann, Ralf
    Pietzsch, Jens
    Wuest, Frank
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2011, 54 (12): : 769 - 774
  • [29] Structure-based design of cyclin-dependent kinase inhibitors
    Davies, TG
    Pratt, DJ
    Endicott, JA
    Johnson, LN
    Noble, MEM
    PHARMACOLOGY & THERAPEUTICS, 2002, 93 (2-3) : 125 - 133
  • [30] Expression of cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors in oligodendrogliomas in humans
    Fiano, V
    Ghimenti, C
    Schiffer, D
    NEUROSCIENCE LETTERS, 2003, 347 (02) : 111 - 115